GENELUX Corp (GNLX) stock
GNLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.00+0.08 (+4.17%)
Close on Nov 17, 2026Market cap $90.49MP/E –Yield –
Genelux cash
Cash and short-term investments held at the end of each period.
Genelux's cash was $18.68M at Jun 30, 2026. For fiscal 2025 it was $5.33M, down 82.7% from the year before. The highest annual figure on record is $30.90M in fiscal 2024.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.33M | -82.7% |
| FY2024 | Dec 31, 2024 | $30.90M | +33.2% |
| FY2023 | Dec 31, 2023 | $23.19M | +5741.6% |
| FY2022 | Dec 31, 2022 | $397.00K | -91.2% |
| FY2021 | Dec 31, 2021 | $4.50M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $18.68M | -33.5% |
| Q1 FY2026 | Mar 31, 2026 | $26.17M | -25.4% |
| Q4 FY2025 | Dec 31, 2025 | $5.33M | -82.7% |
| Q3 FY2025 | Sep 30, 2025 | $20.92M | -40.3% |
| Q2 FY2025 | Jun 30, 2025 | $28.10M | -30.5% |
| Q1 FY2025 | Mar 31, 2025 | $35.10M | +78.8% |
| Q4 FY2024 | Dec 31, 2024 | $30.90M | +33.2% |
| Q3 FY2024 | Sep 30, 2024 | $35.06M | +17.4% |
| Q2 FY2024 | Jun 30, 2024 | $40.45M | +49.0% |
| Q1 FY2024 | Mar 31, 2024 | $19.63M | +89.9% |
| Q4 FY2023 | Dec 31, 2023 | $23.19M | +5741.6% |
| Q3 FY2023 | Sep 30, 2023 | $29.87M | +2080.2% |
| Q2 FY2023 | Jun 30, 2023 | $27.14M | +545.9% |
| Q1 FY2023 | Mar 31, 2023 | $10.34M | +44.1% |
| Q4 FY2022 | Dec 31, 2022 | $397.00K | -91.2% |
| Q3 FY2022 | Sep 30, 2022 | $1.37M | – |
| Q2 FY2022 | Jun 30, 2022 | $4.20M | – |
| Q1 FY2022 | Mar 31, 2022 | $7.18M | – |
| Q4 FY2021 | Dec 31, 2021 | $4.50M | – |
See a number that looks wrong?